AI
Thursday, May 22, 2014 8:19:04 AM
Surprising call by Goldman on Teva. I wish they had said buy MNTA or MNTA calls at the same time 
http://www.theflyonthewall.com/permalinks/entry.php/TEVA;MYLid2014949/TEVA;MYL-Goldman-says-to-buy-TEVA-puts
Goldman says to buy TEVA puts
Goldman said Teva's (TEVA) '808 Copaxone patent expires this weekend, its biggest earnings driver. Mylan (MYL) has stated it expects to launch despite ongoing litigation and Goldman believes FDA approval is likely with a potential May/June launch. The firm believes Teva options are under-priced for volatility around Copaxone and believes shares could trade down 5-10%.
http://www.theflyonthewall.com/permalinks/entry.php/TEVA;MYLid2014949/TEVA;MYL-Goldman-says-to-buy-TEVA-puts
Goldman says to buy TEVA puts
Goldman said Teva's (TEVA) '808 Copaxone patent expires this weekend, its biggest earnings driver. Mylan (MYL) has stated it expects to launch despite ongoing litigation and Goldman believes FDA approval is likely with a potential May/June launch. The firm believes Teva options are under-priced for volatility around Copaxone and believes shares could trade down 5-10%.
Trade Smarter with Thousands
Leverage decades of market experience shared openly.
